Parexel International has expanded its capabilities to provide biopharmaceutical companies with dedicated support for their commercialization goals. PAREXEL has fully integrated its commercialization services to help clients maximize regional and global market access opportunities. These solutions align reimbursement strategies with clinical development to gather the precise data required to demonstrate product value.
“More than ever our clients are faced with the acute need to prove that their products demonstrate value, in addition to safety and efficacy. Biopharmaceutical companies need to address commercialization goals as early as possible to develop products and acquire the right data to receive reimbursement approval in the most efficient way,” said Gadi Saarony, corporate vice president and worldwide head, PAREXEL consulting and medical communications services.
Designed to meet regional and global client needs, PAREXEL commercialization services include: commercialization, reimbursement and market access strategy; payer communications; publication strategy; global value and Academy of Managed Care Pharmacy (AMCP) dossier development; health outcomes analysis and economic modeling.
The PAREXEL commercialization services team includes experts located throughout four continents who bring experience to biopharmaceutical companies in the areas of product management, market access, reimbursement and managed markets, as well as health outcomes, economics, and policy development and modeling. The team includes a cadre of former biopharmaceutical industry leaders, scientific researchers, regulators, and medical writers, as well as product development and management experts. These experts provide solutions for clients that are aligned to the product development and life cycle management processes.